Shanghai Medicilon Inc - Asset Resilience Ratio

Latest as of March 2026: 10.17%

Shanghai Medicilon Inc (688202) has an Asset Resilience Ratio of 10.17% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥281.42 Million

≈ $41.18 Million USD Cash + Short-term Investments

Total Assets

CN¥2.77 Billion

≈ $404.78 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Shanghai Medicilon Inc's Asset Resilience Ratio has changed over time. Check Shanghai Medicilon Inc (688202) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Medicilon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai Medicilon Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥281.42 Million	10.17%
Total Liquid Assets	CN¥281.42 Million	10.17%

Asset Resilience Insights

Moderate Liquidity: Shanghai Medicilon Inc has 10.17% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Shanghai Medicilon Inc Industry Peers by Asset Resilience Ratio

Compare Shanghai Medicilon Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prostemics Co. Ltd KQ:203690	Biotechnology	0.31%
ORUM KQ:475830	Biotechnology	82.74%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
TG Therapeutics Inc NASDAQ:TGTX	Biotechnology	4.72%
Green Cross Holdings Preference Shares KO:005257	Biotechnology	0.50%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	33.70%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Cybin Inc NEO:CYBN	Biotechnology	0.21%

Annual Asset Resilience Ratio for Shanghai Medicilon Inc (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Medicilon Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	4.33%	CN¥113.41 Million ≈ $16.59 Million	CN¥2.62 Billion ≈ $383.69 Million	-4.93pp
2024-12-31	9.25%	CN¥261.22 Million ≈ $38.23 Million	CN¥2.82 Billion ≈ $413.13 Million	-6.62pp
2023-12-31	15.87%	CN¥518.23 Million ≈ $75.83 Million	CN¥3.27 Billion ≈ $477.90 Million	+10.29pp
2021-12-31	5.58%	CN¥100.00 Million ≈ $14.63 Million	CN¥1.79 Billion ≈ $262.46 Million	--

pp = percentage points

About Shanghai Medicilon Inc

SHG:688202 China Biotechnology

Market Cap

$1.61 Billion

CN¥10.99 Billion CNY

Market Cap Rank

#6936 Global

#1453 in China

Share Price

CN¥81.80

Change (1 day)

+3.34%

52-Week Range

CN¥51.31 - CN¥87.35

All Time High

CN¥394.88